Apogee Therapeutics, Inc.
APGE
Clasificación en acciones
#2361
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its... Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
Precio por acción
$135.07
Última sincronización: 2026-09-04
Capitalización bursátil
$8.36B
Cambio (1 día)
0.00%
Cambio (1 año)
137.21%
País
US
Comercio Apogee Therapeutics, Inc. (APGE)
Categoría
Healthcare
Ganancias de Apogee Therapeutics, Inc. (APGE)
Ganancias en Jun 2026 TTM: $-294.09M
Secondo gli ultimi rapporti finanziari di Apogee Therapeutics, Inc., gli utili attuali della società sono $-294.09M. Nel 2023, la società ha registrato un utile di $-83.99M, una disminución en comparación con agli utili del 2022, che erano di $-39.79M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Apogee Therapeutics, Inc. desde 2022 hasta 2026
Ganancias al final de cada año
| Año | Ganancias | Cambiar |
|---|---|---|
| 2026 (TTM) | $-294.09M | 61.48% |
| 2024 | $-182.13M | 116.86% |
| 2023 | $-83.99M | 111.10% |
| 2022 | $-39.79M | 0.00% |
Ganancias de empresas similares o competidoras
| Empresa | Ganancias | Diferencia de ganancias | País |
|---|---|---|---|
| $5.27B | -1,893.62% |
US
|
|
| $-3.09B | 949.67% |
US
|
|
| $-4.02B | 1,265.62% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -763.28% |
NL
|
